Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
11/2000
11/09/2000WO2000066104A2 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000WO2000066102A2 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
11/09/2000WO2000042031A3 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
11/09/2000WO2000041713A3 Composition and method for improving function of embryonic kidney transplants
11/09/2000WO2000038718A3 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
11/09/2000WO2000027422A3 Methods and compositions for treating or preventing peripheral neuropathies
11/09/2000WO2000024780A3 Compositions and methods for treating polycystic kidney disease
11/09/2000WO2000021509A3 Methods of treatment
11/09/2000DE19922443A1 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen Use of dopamine D3 receptor ligands for the preparation of drugs for the treatment of renal dysfunction
11/09/2000DE19920936A1 Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung Heterocyclic substituted benzimidazoles, their preparation and application
11/09/2000CA2388658A1 1-amino triazolo[4,3-a]quinazolin-5-ones and or -5-thiones inhibiting phosphodiesterase iv
11/09/2000CA2372923A1 Dna encoding snorf36a and snorf36b receptors
11/09/2000CA2372387A1 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000CA2372223A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000CA2372220A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000CA2371758A1 2,1-benzisothiazoline 2,2-dioxides
11/09/2000CA2371757A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000CA2371651A1 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
11/09/2000CA2371642A1 Cyclic urea and cyclic amide derivatives
11/09/2000CA2371638A1 Indoline derivatives as progesterone antagonists
11/09/2000CA2371633A1 Thio-oxindole derivatives
11/09/2000CA2371629A1 3,3-substituted indoline derivatives
11/09/2000CA2371604A1 Integrin receptor antagonists
11/09/2000CA2371391A1 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
11/09/2000CA2370304A1 Specific antibodies and antibody fragments for tgf.beta.1
11/09/2000CA2366805A1 Benzimidazolones and analogues and their use as progesterone receptor ligands
11/09/2000CA2338799A1 Protein c derivatives
11/08/2000EP1050307A1 CCR4 antagonists in sepsis
11/08/2000EP1049695A1 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
11/08/2000EP1049691A1 Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
11/08/2000EP1049677A1 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
11/08/2000EP1049472A1 Antagonists of gonadotropin releasing hormone
11/08/2000EP1049441A2 Pharmaceutical compositions comprising thiram for inhibiting angiogenesis
11/08/2000EP0734396B1 ANALOGUES OF hGH-RH (1-29)NH2 HAVING ANTAGONISTIC ACTIVITY
11/08/2000EP0655089B1 Effects of actin filaments on fibrin clot structure and lysis
11/08/2000CN1272786A Endothelin antagonist and beta receptor blocking agent as combined preparation
11/08/2000CN1058262C Novel 1-phenylalkanone 5-HT4 receptor ligands
11/07/2000US6143886 Azepinone compounds useful in the inhibition of ACE and NEP
11/07/2000US6143864 Peptides
11/07/2000US6143783 Amino acids
11/07/2000US6143779 Benzofuranone derivatives and a method for producing them
11/07/2000US6143746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
11/07/2000US6143521 Human bombesin receptor subtype-3sb
11/02/2000WO2000065346A1 Diagnosis of human kidney diseases
11/02/2000WO2000065054A2 Human membrane-associated proteins
11/02/2000WO2000065027A2 Human gil-19/ae289 proteins and polynucleotides encoding same
11/02/2000WO2000064900A1 Pyrazolobenzodiazepines as cdk2 inhibitors
11/02/2000WO2000064899A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands
11/02/2000WO2000064892A2 Thiazolidinedione derivative and its use as antidiabetic
11/02/2000WO2000064887A1 Renin inhibitors
11/02/2000WO2000064878A1 Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors
11/02/2000WO2000064873A1 Renin inhibitors
11/02/2000WO2000064486A2 Enzymatically activated polymeric drug conjugates
11/02/2000WO2000064474A1 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
11/02/2000WO2000064468A2 Therapeutic compositions and methods for enhancing angiogenesis
11/02/2000WO2000064421A2 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
11/02/2000WO2000046235B1 Novel betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors
11/02/2000WO2000042042A3 High affinity inhibitors for target validation and uses thereof
11/02/2000WO2000040714A3 Therapeutic phosphodiesterase inhibitors
11/02/2000WO2000038730A3 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
11/02/2000WO1999063973A3 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
11/02/2000EP1048725A1 Process for production of mammalian cell lines, produced cell lines and their uses
11/02/2000EP1048657A1 Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
11/02/2000EP1047776A2 Therapeutic composition comprising the kal protein and use of the kal protein
11/02/2000CA2371242A1 Diagnosis of human kidney diseases
11/02/2000CA2371046A1 Therapeutic compositions and methods for enhancing angiogenesis
11/02/2000CA2370258A1 Thiazolidinedione derivative and its use as antidiabetic
11/02/2000CA2370195A1 Human membrane-associated proteins
11/02/2000CA2369999A1 Enzymatically activated polymeric drug conjugates
11/02/2000CA2369942A1 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
11/02/2000CA2367965A1 Human gil-19/ae289 proteins and polynucleotides encoding same
11/02/2000CA2367682A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands
11/01/2000CN1272111A Tricyclic vasopressin agonists
11/01/2000CN1272110A Tricyclic vasopressin agonists
11/01/2000CN1058019C 环状氨基酸衍生物 Cyclic amino acid derivatives
10/2000
10/31/2000US6140466 Comprises at least three zinc finger domains that bind to target cellular nucleotide sequence and modulate its transcription; genome-specific transcriptional switches in gene therapy; transgenic plants and animals
10/31/2000US6140355 Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
10/31/2000US6140352 Carbazolyl-substituted ethanolamines as selective β-3 agonists
10/31/2000US6140334 For treating high blood pressure, benign prostate hyperplasia
10/31/2000US6140329 For treating a male animal for erectile dysfunction
10/27/2000CA2307108A1 Process for production of mammalian cell lines, produced cell lines and their uses
10/26/2000WO2000063702A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes
10/26/2000WO2000063247A2 Osteopontin-derived chemotactic and inhibitory agents and uses therefor
10/26/2000WO2000063241A2 Methods and compositions for modulating an immune response
10/26/2000WO2000063204A2 Substituted azoles
10/26/2000WO2000063194A1 Sulfonamide derivatives having oxadiazole rings
10/26/2000WO2000063191A1 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
10/26/2000WO2000063190A1 New compounds, their preparation and use
10/26/2000WO2000063181A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins
10/26/2000WO2000063178A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
10/26/2000WO2000063170A1 Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase 5
10/26/2000WO2000063160A1 2-alkoxy-cyclobutene-3,4-dione derivatives, preparation and therapeutic use thereof
10/26/2000WO2000063153A1 New compounds, their preparation and use
10/26/2000WO2000062797A1 Remedies for autonomic neuropathy
10/26/2000WO2000062773A1 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects
10/26/2000WO2000062766A2 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/26/2000WO2000039275A3 Multiple shear stress responsive elements (ssre) and methods of use thereof
10/26/2000WO2000039120A3 Compounds and methods for modulation of estrogen receptors
10/26/2000WO2000035886A3 (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
10/26/2000WO2000028045A3 Human hydrolase proteins
1 ... 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 ... 562